Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Earnings Results, Misses Expectations By $0.79 EPS

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) posted its earnings results on Monday. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.79), Zacks reports. The business had revenue of $7.68 million during the quarter, compared to the consensus estimate of $86.32 million.

Syndax Pharmaceuticals Stock Down 1.3 %

Shares of SNDX stock traded down $0.19 during trading hours on Thursday, reaching $14.29. 2,468,872 shares of the stock traded hands, compared to its average volume of 2,330,111. Syndax Pharmaceuticals has a 1-year low of $12.06 and a 1-year high of $25.16. The firm has a market capitalization of $1.22 billion, a PE ratio of -3.94 and a beta of 0.90. The business has a fifty day moving average price of $14.29 and a 200 day moving average price of $16.69.

Wall Street Analysts Forecast Growth

SNDX has been the subject of several recent research reports. StockNews.com lowered shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, November 23rd. Citigroup dropped their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday. The Goldman Sachs Group raised their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. HC Wainwright reiterated a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday. Finally, Scotiabank dropped their price target on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $36.00.

Remove Ads

Insider Transactions at Syndax Pharmaceuticals

In other news, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the transaction, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. This represents a 4.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Neil Gallagher sold 4,618 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the sale, the insider now owns 85,095 shares of the company's stock, valued at $1,318,972.50. This represents a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,683 shares of company stock valued at $336,087 over the last three months. 4.10% of the stock is owned by corporate insiders.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).